Equities Analysts Set Expectations for IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Ironwood Pharmaceuticals in a report issued on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

A number of other equities analysts have also weighed in on the stock. JMP Securities reduced their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research note on Thursday, January 30th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $8.60.

Ironwood Pharmaceuticals Stock Down 3.4 %

Shares of IRWD stock opened at $1.41 on Friday. Ironwood Pharmaceuticals has a 12-month low of $1.34 and a 12-month high of $8.64. The firm has a fifty day moving average of $2.04 and a 200-day moving average of $3.38. The company has a market capitalization of $225.64 million, a price-to-earnings ratio of -47.00 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million.

Insider Activity at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. raised its stake in Ironwood Pharmaceuticals by 150.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company’s stock valued at $520,000 after buying an additional 75,917 shares during the period. Intech Investment Management LLC bought a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at $181,000. Charles Schwab Investment Management Inc. lifted its holdings in Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after purchasing an additional 364,841 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in Ironwood Pharmaceuticals by 21.2% during the third quarter. Daiwa Securities Group Inc. now owns 67,570 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 11,800 shares during the period. Finally, FMR LLC increased its holdings in shares of Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 34,089 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.